Biden Administration Set to Announce First Round of Drugs to Be Eligible for Medicare Negotiation by Sept. 1
New Hart Research polling on behalf of Protect Our Care confirms the popularity of the Inflation Reduction Act’s Medicare Drug Negotiation Program. This week, the Biden administration is expected to announce the first round of drugs subject to negotiations. These drugs are likely to be some of the costliest medications on the market and treat conditions like cancer, autoimmune disorders, and diabetes.
The new polling shows that 96 percent of Americans agree that lower drug prices “is an important way to help people afford the cost of living,” and nearly three-quarters of Americans favor Democrats’ move to pass Medicare negotiation. Meanwhile, pharmaceutical companies’ arguments against negotiation are overwhelmingly rejected by the American people. A closer look at the results:
73 percent of Americans support President Biden and Democrats in Congress passing legislation to give Medicare the power to negotiate lower drug prices:
The pharmaceutical industry and drug companies are extremely unpopular, with more than 7 in 10 reporting an unfavorable view of drug companies:
Americans reject drug companies’ arguments that Medicare negotiation will hurt innovation: